Drug Pricing Center
![pills-943764_1920[1]](https://eadn-wc03-6094147.nxedge.io/wp-content/uploads/2015/01/pills-943764_19201-1500x430.jpg)
Resources
Five Years of State Action to Lower Drug Prices: 2017-2021, May 2021
Pharmacy Cost Work Group MembersEd Achuck, Pharmacy Section Chief, California Department of General Services
Susan Barrett, Executive Director, Green Mountain Care Board, Vermont
Burl Beasley, Director, Pharmacy Services, Oklahoma Office of Management and Enterprise Services
Terry Cothran, Senior Pharmacy Director, Oklahoma Health Care Authority
James DeBenedetti, Director of Plan Management, Covered California
Richard Gottfried, State Assemblyman and Chair of Committee on Health, New York State Assembly, District 75
Kaha Hizanishvili, Chief, Provider and Pharmacy Programs, MassHealth, Massachussetts Executive Office of Health and Human Services
Sonya Jaquez Lewis, State Senator, Colorado State Senate, District 17
Eileen Mallow, Director, Office of Strategic Health Policy, Wisconsin Department of Employee Trust Funds
Kevin Martin, Pharmacy Rates Analyst, Colorado Department of Health Care Policy and Financing
Sara Sadownik, Deputy Director, Research and Cost Trends, Massachusetts Health Policy Commission
David Seltz, Executive Director, Massachusetts Health Policy Commission
Tricia Sieg, Pharmacy Benefit Program Manager, Wisconsin Department of Employee Trust Funds
Donna Sullivan, Chief Pharmacy Officer, Washington State Health Care Authority
Norman Thurston, State Representative, Utah House of Representatives, District 64
Joshua Wojcik, Assistant Comptroller, Connecticut Office of the Comptroller
Andrew York, Executive Director, Maryland Prescription Drug Affordability Board
To learn more about the Center or to receive state-only materials contact Jennifer Reck (jreck@oldsite.nashp.org)
Sign Up for Our Weekly Newsletter
Sign Up for Our Weekly Newsletter
Washington, DC Office:
1233 20th St., N.W., Suite 303Washington, DC 20036
p: (202) 903-0101
f: (202) 903-2790
Contact Us
Phone: 202-903-0101

For individuals living with complex, often chronic conditions, and their families, palliative care can provide relief from symptoms, improve satisfaction and outcomes, and help address critical mental and spiritual needs during difficult times. Now more than ever, there is growing recognition of the importance of palliative care services for individuals with serious illness, such as advance care planning, pain and symptom management, care coordination, and team-based, multi-disciplinary support. These services can help patients and families cope with the symptoms and stressors of disease, better anticipate and avoid crises, and reduce unnecessary and/or unwanted care. While this model is grounded in evidence that demonstrates improved quality of life, better outcomes, and reduced cost for patients, only a fraction of individuals who could benefit from palliative care receive it. 
























































































































































Trending Now: State Legislation that Bans Pharmacy Benefit Managers’ “Gag Clauses”
/in Policy Blogs Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by LaVita TuffA growing number of state legislatures across the country are introducing bills to outlaw a “gag clause” that prevents pharmacists from telling consumers when there are cheaper prescription drug alternatives available. Some of the bills also require fuller disclosure about the business relationships between pharmacy benefit managers, health plans, and pharmacies in order to address […]
State Legislatures Start Out Strong in 2018 with Bills to Curb Rx Drug Costs
/in Policy Blogs Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersWith the federal government continuing to take no action to curb drug costs, states legislatures across the country are intensifying their efforts in 2018 to staunch the financial hemorrhage to health care budgets caused by escalating prescription drug costs. Three weeks into 2018, 43 bills designed to rein in prescription drug costs have been introduced […]
Maryland Lawmakers Submit Drug Cost Review Bill Based on NASHP’s Model Legislation
/in Policy Blogs Administrative Actions, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffANNAPOLIS — State lawmakers are scheduled to introduce a bill today that empowers Maryland to regulate prescription drug costs by evaluating the affordability of certain drugs and imposing limits on what the state and commercial health plans will pay them. Based on model legislation created by the National Academy for State Health Policy (NASHP), the […]
State Legislative Action to Lower Pharmaceutical Costs
/in Policy Administrative Actions, Health Coverage and Access, Prescription Drug Pricing, State Rx Legislative Action /by LaVita Tuff*Updated Oct. 4, 2018* Find the status of state legislation to curb prescription drugs below. Use the category button to search by type of legislation or click on a state to view its drug bills. Click here to view a chart listing legislation by state. View state action in 2017 and 2015-2016. Know about a bill to add or have information to […]
Utah State Legislator Introduces Bill to Import Prescription Drugs from Canada, Based on NASHP Model Legislation
/in Policy Utah Blogs Administrative Actions, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffSalt Lake City, Utah: Today, Republican state legislator Norman Thurston introduced groundbreaking legislation to create a safe, state-run prescription drug importation program that would import high-cost drugs from Canada, where prescription drugs cost 30 percent less than in the United States. The proposal for a whole-sale importation program of select, higher-cost drugs that are already […]
Reining in Rx Drug Costs: What States Achieved in 2017 and Where They’re Heading in 2018
/in Policy Blogs Administrative Actions, Health Coverage and Access, Model Legislation, Prescription Drug Pricing, State Rx Legislative Action /by Corinne AlbertsIn a year of tense partisan debate over the future of health care, one issue has achieved rare bipartisan agreement — the need to curb rising prescription drug costs. Polls show again and again that Americans, regardless of political affiliation, view the high costs of drugs as one of their chief health care concerns. Reviews […]
Academy of Sciences Recommends Federal Strategies to Lower Rx Prices, But Some States Are Already Taking Action
/in Policy Administrative Actions, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersThe National Academy of Sciences recently released a report recommending several strategies to curb prescription drug costs that attempt to strike a balance between reining in prices while fostering continued drug development and innovation. Several of the academy’s recommendations are already getting trial runs in states, which are experimenting with innovative cost-savings approaches in order […]
Is It Safe and Cost-Effective to Import Drugs from Canada?
/in Policy Administrative Actions, Model Legislation, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffStates are considering importing prescription drugs from Canada, but is it safe? Will it save money? Can it be done? Three, easy-to-read infographics explain what state leaders need to know if they’re interested in drug importation legislation. 1. Is it safe to import drugs from Canada? Yes, 40 percent of all drugs sold in the […]
The Dormant Commerce Clause: What Impact Does It Have on the Regulation of Pharmaceutical Costs?
/in Policy Reports Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP StaffWhen states pass laws designed to control prescription drug costs, the pharmaceutical industry often responds with lawsuits claiming states are hindering interstate commerce and violating the federal Dormant Commerce Clause (DCC). NASHP’s legal experts believe states can craft drug cost policies that can withstand industry challenges. This brief by Anna Zaret and Darien Shankse provides insight and […]
How States Can Avoid Dormant Commerce Clause Legal Challenges When Regulating Drug Costs
/in Policy Maryland, Nevada Blogs Administrative Actions, Legal Resources, Newly-Enacted Laws, Prescription Drug Pricing, State Rx Legislative Action /by NASHP WritersNew state laws designed to control the costs of brand-name and generic prescription drugs often face legal challenges from the pharmaceutical industry. These lawsuits can vary depending on the individual state law, but recent industry lawsuits analyzed by the National Academy for State Health Policy (NASHP) share a common legal thread – drug manufacturers and […]